IVAX Corporation

IVAX Launches Amoxicillin With Clavulanate Potassium

IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced that its wholly
owned subsidiary, IVAX Pharmaceuticals, Inc. is distributing
amoxicillin with clavulanate potassium, supplied and licensed by
GlaxoSmithKline (LSE and NYSE:GSK). Amoxicillin with clavulnate
potassium is an oral antibacterial combination used for the treatment
of respiratory, urinary and skin infections; and is the generic
equivalent of Augmentin(R), which is marketed by GlaxoSmithKline. U.S.
sales for amoxicillin with clavulanate potassium were $1.4 billion for
the twelve months ending September 30, 2003.

IVAX Corporation, headquartered in Miami, Florida, discovers,
develops, manufactures, and markets branded and brand equivalent
(generic) pharmaceuticals and veterinary products in the U.S. and
internationally.

Copies of this and other news releases may be obtained free of
charge from IVAX' website at http://www.ivax.com.